Next Article in Journal
A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells
Next Article in Special Issue
Epidemiological Identification of A Novel Pathogen in Real Time: Analysis of the Atypical Pneumonia Outbreak in Wuhan, China, 2019–2020
Previous Article in Journal
The Relationship Between Gastrointestinal Comorbidities, Clinical Presentation and Surgical Outcome in Patients with DCM: Analysis of a Global Cohort
Previous Article in Special Issue
Assessing the Impact of Reduced Travel on Exportation Dynamics of Novel Coronavirus Infection (COVID-19)
Open AccessReview

Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review

1
Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117549, Singapore
2
Centre for Infectious Disease Epidemiology and Research, National University of Singapore, Singapore 117549, Singapore
3
National Centre for Infectious Diseases, Singapore 308442, Singapore
4
Ministry of Health, Singapore 169854, Singapore
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(3), 623; https://doi.org/10.3390/jcm9030623
Received: 13 February 2020 / Revised: 17 February 2020 / Accepted: 19 February 2020 / Published: 26 February 2020
Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published. A commercial RT-PCR kit developed by the Beijing Genomic Institute is currently widely used in China and likely in Asia. However, serological assays as well as point-of-care testing kits have not been developed but are likely in the near future. Several vaccine candidates are in the pipeline. The likely earliest Phase 1 vaccine trial is a synthetic DNA-based candidate. A number of novel compounds as well as therapeutics licensed for other conditions appear to have in vitro efficacy against the 2019-nCoV. Some are being tested in clinical trials against MERS-CoV and SARS-CoV, while others have been listed for clinical trials against 2019-nCoV. However, there are currently no effective specific antivirals or drug combinations supported by high-level evidence. View Full-Text
Keywords: novel coronavirus; diagnostics; vaccine; treatments; global health; outbreak; MERS-CoV; SARS-CoV novel coronavirus; diagnostics; vaccine; treatments; global health; outbreak; MERS-CoV; SARS-CoV
Show Figures

Figure 1

MDPI and ACS Style

Pang, J.; Wang, M.X.; Ang, I.Y.H.; Tan, S.H.X.; Lewis, R.F.; Chen, J. .-P.; Gutierrez, R.A.; Gwee, S.X.W.; Chua, P.E.Y.; Yang, Q.; Ng, X.Y.; Yap, R.K.; Tan, H.Y.; Teo, Y.Y.; Tan, C.C.; Cook, A.R.; Yap, J. .-H.; Hsu, L.Y. Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review. J. Clin. Med. 2020, 9, 623.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop